Back to Journals » OncoTargets and Therapy » Volume 6

Systematic review of dasatinib in chronic myeloid leukemia

Authors Breccia M, Salaroli A, Molica M, Alimena G

Received 12 January 2013

Accepted for publication 7 March 2013

Published 27 March 2013 Volume 2013:6 Pages 257—265


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Massimo Breccia, Adriano Salaroli, Matteo Molica, Giuliana Alimena

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy

Abstract: Dasatinib is a dual tyrosine kinase inhibitor active against ABL and Src family kinases, and is approved for the treatment of chronic myeloid leukemia (CML) patients in chronic, accelerated, or blast phase with resistance or intolerance to imatinib therapy, for newly diagnosed chronic phase patients, and for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia who have become resistant to or intolerant of other treatments. This review presents clinical data regarding different trials involving CML patients in different phases of the disease. Six-year follow-up of the Phase III dose-optimization study are described, showing overall survival of 71% with the current approved dose of 100 mg once daily. Three-year results of the randomized Phase III DASISION (DASatinib vs Imatinib Study In Treatment-Naïve CML patients) trial confirmed that dasatinib 100 mg once daily was superior to standard-dose imatinib in terms of achieving a faster and deeper molecular response, with similar activity regardless of baseline prognostic score.

Keywords: chronic myeloid leukemia, acute lymphoblastic leukemia, dasatinib

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.